Pharmaceutical

Japan approves updated Covid-19 vaccine to tackle JN.1 ...

Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a...

Sanofi inaugurates vaccine plant in Neuville-sur-Saône,...

Sanofi has announced the inauguration its new modular vaccine and biomedicine pr...

Gilead and Genesis partner to create novel therapies us...

Gilead Sciences has partnered with Genesis Therapeutics to discover and develop ...

Prodrugs and patents: Enhancing therapy adherence and r...

As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, ...

FDA grants breakthrough therapy designation to Neurapti...

The FDA has granted breakthrough therapy designation to Neuraptive Therapeutics’...

FDA approves Johnson & Johnson’s TREMFYA for ulcerative...

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the tre...

EASD 2024: Are tetra-agonists the future of metabolic d...

EASD 2024 participants are looking for the hottest efficacy data to make predict...

IBA venture PanTera gains €134m in funding to scale up ...

The IBA-SCK CEN joint venture secured funds to increase production of the radioi...

EASD 2024: Novo Nordisk’s Saxenda shows weight loss in ...

Children aged 6-12 years achieved a 5.8% reduction in BMI with Novo Nordisk's Sa...

NanoSyrinx secures funds to develop biologic therapeutics

NanoSyrinx has secured £10m ($13m) aimed at advancing its technology for targete...

FDA grants breakthrough therapy status to Arrowhead’s p...

The US FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuti...

CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihoo...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

Sildenafil citrate by XOMA Royalty for Female Hypoactiv...

Sildenafil citrate is under clinical development by XOMA Royalty and currently i...

CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Li...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Follicular Lymphoma: Likelihood...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...